KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Total Debt (2017 - 2023)

Bionano Genomics' Total Debt history spans 5 years, with the latest figure at $10.0 million for Q3 2023.

  • For Q3 2023, Total Debt rose 7.49% year-over-year to $10.0 million; the TTM value through Sep 2023 reached $10.0 million, up 7.49%, while the annual FY2022 figure was $9.4 million, N/A changed from the prior year.
  • Total Debt for Q3 2023 was $10.0 million at Bionano Genomics, roughly flat from $10.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $20.1 million in Q4 2019 and bottomed at $9.2 million in Q2 2022.
  • The 5-year median for Total Debt is $15.7 million (2020), against an average of $14.3 million.
  • The largest annual shift saw Total Debt fell 19.09% in 2020 before it grew 8.41% in 2023.
  • A 5-year view of Total Debt shows it stood at $20.1 million in 2019, then fell by 18.72% to $16.3 million in 2020, then fell by 8.94% to $14.9 million in 2021, then crashed by 36.89% to $9.4 million in 2022, then increased by 6.59% to $10.0 million in 2023.
  • Per Business Quant, the three most recent readings for BNGO's Total Debt are $10.0 million (Q3 2023), $10.0 million (Q2 2023), and $9.5 million (Q1 2023).